Terumo Corporation

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SRTOY has a market cap of 181B. Regarding current trading prices, TRUMY is priced at $12.90, while SRTOY trades at $18.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SRTOY's P/E ratio is 60.00. In terms of profitability, TRUMY's ROE is +0.09%, compared to SRTOY's ROE of +0.06%. Regarding short-term risk, TRUMY is less volatile compared to SRTOY. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check SRTOY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, ESLOF has a market cap of 108.3B. Regarding current trading prices, TRUMY is priced at $12.90, while ESLOF trades at $233.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas ESLOF's P/E ratio is 40.74. In terms of profitability, TRUMY's ROE is +0.09%, compared to ESLOF's ROE of +0.06%. Regarding short-term risk, TRUMY is more volatile compared to ESLOF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check ESLOF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, ESLOY has a market cap of 108.1B. Regarding current trading prices, TRUMY is priced at $12.90, while ESLOY trades at $116.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas ESLOY's P/E ratio is 40.53. In terms of profitability, TRUMY's ROE is +0.09%, compared to ESLOY's ROE of +0.06%. Regarding short-term risk, TRUMY is more volatile compared to ESLOY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check ESLOY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, MECNY has a market cap of 107.5B. Regarding current trading prices, TRUMY is priced at $12.90, while MECNY trades at $88.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas MECNY's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to MECNY's ROE of +0.02%. Regarding short-term risk, TRUMY is more volatile compared to MECNY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check MECNY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SOAGY has a market cap of 70B. Regarding current trading prices, TRUMY is priced at $12.90, while SOAGY trades at $47.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SOAGY's P/E ratio is 92.12. In terms of profitability, TRUMY's ROE is +0.09%, compared to SOAGY's ROE of +0.06%. Regarding short-term risk, TRUMY is more volatile compared to SOAGY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SOAGY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, HOCPF has a market cap of 63.2B. Regarding current trading prices, TRUMY is priced at $12.90, while HOCPF trades at $187.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas HOCPF's P/E ratio is 48.57. In terms of profitability, TRUMY's ROE is +0.09%, compared to HOCPF's ROE of +0.25%. Regarding short-term risk, TRUMY is more volatile compared to HOCPF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check HOCPF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, HOCPY has a market cap of 58.4B. Regarding current trading prices, TRUMY is priced at $12.90, while HOCPY trades at $172.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas HOCPY's P/E ratio is 45.21. In terms of profitability, TRUMY's ROE is +0.09%, compared to HOCPY's ROE of +0.25%. Regarding short-term risk, TRUMY is more volatile compared to HOCPY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check HOCPY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, RSMDF has a market cap of 32B. Regarding current trading prices, TRUMY is priced at $12.90, while RSMDF trades at $21.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas RSMDF's P/E ratio is 22.64. In terms of profitability, TRUMY's ROE is +0.09%, compared to RSMDF's ROE of +0.25%. Regarding short-term risk, TRUMY is less volatile compared to RSMDF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check RSMDF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, TRUMF has a market cap of 20.3B. Regarding current trading prices, TRUMY is priced at $12.90, while TRUMF trades at $13.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas TRUMF's P/E ratio is 24.62. In terms of profitability, TRUMY's ROE is +0.09%, compared to TRUMF's ROE of +0.09%. Regarding short-term risk, TRUMY is less volatile compared to TRUMF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check TRUMF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SUVPF has a market cap of 18.7B. Regarding current trading prices, TRUMY is priced at $12.90, while SUVPF trades at $271.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SUVPF's P/E ratio is 104.26. In terms of profitability, TRUMY's ROE is +0.09%, compared to SUVPF's ROE of +0.06%. Regarding short-term risk, TRUMY is less volatile compared to SUVPF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check SUVPF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SDMHF has a market cap of 18B. Regarding current trading prices, TRUMY is priced at $12.90, while SDMHF trades at $185.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SDMHF's P/E ratio is 58.54. In terms of profitability, TRUMY's ROE is +0.09%, compared to SDMHF's ROE of +0.07%. Regarding short-term risk, TRUMY is more volatile compared to SDMHF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SDMHF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SAUHY has a market cap of 16.4B. Regarding current trading prices, TRUMY is priced at $12.90, while SAUHY trades at $10.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SAUHY's P/E ratio is 35.45. In terms of profitability, TRUMY's ROE is +0.09%, compared to SAUHY's ROE of +0.17%. Regarding short-term risk, TRUMY is more volatile compared to SAUHY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SAUHY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SAUHF has a market cap of 16.3B. Regarding current trading prices, TRUMY is priced at $12.90, while SAUHF trades at $101.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SAUHF's P/E ratio is 35.52. In terms of profitability, TRUMY's ROE is +0.09%, compared to SAUHF's ROE of +0.17%. Regarding short-term risk, TRUMY is more volatile compared to SAUHF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SAUHF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SARTF has a market cap of 15.6B. Regarding current trading prices, TRUMY is priced at $12.90, while SARTF trades at $226.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SARTF's P/E ratio is 87.05. In terms of profitability, TRUMY's ROE is +0.09%, compared to SARTF's ROE of +0.06%. Regarding short-term risk, TRUMY is more volatile compared to SARTF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SARTF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, CLPBY has a market cap of 15.6B. Regarding current trading prices, TRUMY is priced at $12.90, while CLPBY trades at $6.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas CLPBY's P/E ratio is 25.59. In terms of profitability, TRUMY's ROE is +0.09%, compared to CLPBY's ROE of +0.25%. Regarding short-term risk, TRUMY is more volatile compared to CLPBY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check CLPBY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, CLPBF has a market cap of 14.5B. Regarding current trading prices, TRUMY is priced at $12.90, while CLPBF trades at $69.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas CLPBF's P/E ratio is 25.07. In terms of profitability, TRUMY's ROE is +0.09%, compared to CLPBF's ROE of +0.25%. Regarding short-term risk, TRUMY is more volatile compared to CLPBF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check CLPBF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SSSGY has a market cap of 14.5B. Regarding current trading prices, TRUMY is priced at $12.90, while SSSGY trades at $41.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SSSGY's P/E ratio is 80.59. In terms of profitability, TRUMY's ROE is +0.09%, compared to SSSGY's ROE of +0.06%. Regarding short-term risk, TRUMY is more volatile compared to SSSGY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SSSGY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, FSPKF has a market cap of 13.1B. Regarding current trading prices, TRUMY is priced at $12.90, while FSPKF trades at $22.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas FSPKF's P/E ratio is 50.70. In terms of profitability, TRUMY's ROE is +0.09%, compared to FSPKF's ROE of +0.30%. Regarding short-term risk, TRUMY is more volatile compared to FSPKF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check FSPKF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, OCPNF has a market cap of 9B. Regarding current trading prices, TRUMY is priced at $12.90, while OCPNF trades at $8.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas OCPNF's P/E ratio is 14.93. In terms of profitability, TRUMY's ROE is +0.09%, compared to OCPNF's ROE of +0.11%. Regarding short-term risk, TRUMY is less volatile compared to OCPNF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check OCPNF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, CNVVF has a market cap of 6.6B. Regarding current trading prices, TRUMY is priced at $12.90, while CNVVF trades at $3.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas CNVVF's P/E ratio is 37.78. In terms of profitability, TRUMY's ROE is +0.09%, compared to CNVVF's ROE of +0.11%. Regarding short-term risk, TRUMY is less volatile compared to CNVVF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check CNVVF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, CNVVY has a market cap of 6.1B. Regarding current trading prices, TRUMY is priced at $12.90, while CNVVY trades at $12.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas CNVVY's P/E ratio is 36.86. In terms of profitability, TRUMY's ROE is +0.09%, compared to CNVVY's ROE of +0.10%. Regarding short-term risk, TRUMY is more volatile compared to CNVVY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check CNVVY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SSMXF has a market cap of 5.6B. Regarding current trading prices, TRUMY is priced at $12.90, while SSMXF trades at $9.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SSMXF's P/E ratio is 19.15. In terms of profitability, TRUMY's ROE is +0.09%, compared to SSMXF's ROE of +0.09%. Regarding short-term risk, TRUMY is more volatile compared to SSMXF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SSMXF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, AHICF has a market cap of 5.4B. Regarding current trading prices, TRUMY is priced at $12.90, while AHICF trades at $20.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas AHICF's P/E ratio is 48.50. In terms of profitability, TRUMY's ROE is +0.09%, compared to AHICF's ROE of +0.12%. Regarding short-term risk, TRUMY is less volatile compared to AHICF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check AHICF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SSMXY has a market cap of 5.4B. Regarding current trading prices, TRUMY is priced at $12.90, while SSMXY trades at $8.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SSMXY's P/E ratio is 19.27. In terms of profitability, TRUMY's ROE is +0.09%, compared to SSMXY's ROE of +0.09%. Regarding short-term risk, TRUMY is more volatile compared to SSMXY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SSMXY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, YPHDF has a market cap of 5.2B. Regarding current trading prices, TRUMY is priced at $12.90, while YPHDF trades at $381.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas YPHDF's P/E ratio is 21.01. In terms of profitability, TRUMY's ROE is +0.09%, compared to YPHDF's ROE of +0.30%. Regarding short-term risk, TRUMY is more volatile compared to YPHDF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check YPHDF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, ADDLF has a market cap of 4.9B. Regarding current trading prices, TRUMY is priced at $12.90, while ADDLF trades at $42.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas ADDLF's P/E ratio is 61.76. In terms of profitability, TRUMY's ROE is +0.09%, compared to ADDLF's ROE of +0.11%. Regarding short-term risk, TRUMY is less volatile compared to ADDLF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check ADDLF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, FLMNF has a market cap of 4.4B. Regarding current trading prices, TRUMY is priced at $12.90, while FLMNF trades at $52.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas FLMNF's P/E ratio is 20.97. In terms of profitability, TRUMY's ROE is +0.09%, compared to FLMNF's ROE of +0.20%. Regarding short-term risk, TRUMY is more volatile compared to FLMNF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check FLMNF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, FLMNY has a market cap of 4.2B. Regarding current trading prices, TRUMY is priced at $12.90, while FLMNY trades at $9.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas FLMNY's P/E ratio is 19.87. In terms of profitability, TRUMY's ROE is +0.09%, compared to FLMNY's ROE of +0.20%. Regarding short-term risk, TRUMY is more volatile compared to FLMNY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check FLMNY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, ANSLF has a market cap of 3.3B. Regarding current trading prices, TRUMY is priced at $12.90, while ANSLF trades at $22.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas ANSLF's P/E ratio is 32.49. In terms of profitability, TRUMY's ROE is +0.09%, compared to ANSLF's ROE of +0.07%. Regarding short-term risk, TRUMY is more volatile compared to ANSLF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check ANSLF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SHWGF has a market cap of 3.3B. Regarding current trading prices, TRUMY is priced at $12.90, while SHWGF trades at $0.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SHWGF's P/E ratio is 12.17. In terms of profitability, TRUMY's ROE is +0.09%, compared to SHWGF's ROE of +0.08%. Regarding short-term risk, TRUMY is more volatile compared to SHWGF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SHWGF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, ANSLY has a market cap of 3B. Regarding current trading prices, TRUMY is priced at $12.90, while ANSLY trades at $84.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas ANSLY's P/E ratio is 22.63. In terms of profitability, TRUMY's ROE is +0.09%, compared to ANSLY's ROE of +0.07%. Regarding short-term risk, TRUMY is more volatile compared to ANSLY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check ANSLY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SHWGY has a market cap of 2.9B. Regarding current trading prices, TRUMY is priced at $12.90, while SHWGY trades at $2.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SHWGY's P/E ratio is 10.20. In terms of profitability, TRUMY's ROE is +0.09%, compared to SHWGY's ROE of +0.08%. Regarding short-term risk, TRUMY is more volatile compared to SHWGY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SHWGY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, CZMWF has a market cap of 2.6B. Regarding current trading prices, TRUMY is priced at $12.90, while CZMWF trades at $30.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas CZMWF's P/E ratio is 16.04. In terms of profitability, TRUMY's ROE is +0.09%, compared to CZMWF's ROE of +0.07%. Regarding short-term risk, TRUMY is less volatile compared to CZMWF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check CZMWF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, CZMWY has a market cap of 2.4B. Regarding current trading prices, TRUMY is priced at $12.90, while CZMWY trades at $26.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas CZMWY's P/E ratio is 14.62. In terms of profitability, TRUMY's ROE is +0.09%, compared to CZMWY's ROE of +0.06%. Regarding short-term risk, TRUMY is more volatile compared to CZMWY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check CZMWY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, TCGGY has a market cap of 2.3B. Regarding current trading prices, TRUMY is priced at $12.90, while TCGGY trades at $36.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas TCGGY's P/E ratio is 27.27. In terms of profitability, TRUMY's ROE is +0.09%, compared to TCGGY's ROE of +0.05%. Regarding short-term risk, TRUMY is less volatile compared to TCGGY. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check TCGGY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, EKTAF has a market cap of 2.3B. Regarding current trading prices, TRUMY is priced at $12.90, while EKTAF trades at $6.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas EKTAF's P/E ratio is -620.00. In terms of profitability, TRUMY's ROE is +0.09%, compared to EKTAF's ROE of -0.00%. Regarding short-term risk, TRUMY is more volatile compared to EKTAF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check EKTAF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, EKTAY has a market cap of 2.2B. Regarding current trading prices, TRUMY is priced at $12.90, while EKTAY trades at $5.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas EKTAY's P/E ratio is -588.00. In terms of profitability, TRUMY's ROE is +0.09%, compared to EKTAY's ROE of -0.00%. Regarding short-term risk, TRUMY is more volatile compared to EKTAY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check EKTAY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, TCHBF has a market cap of 2B. Regarding current trading prices, TRUMY is priced at $12.90, while TCHBF trades at $156.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas TCHBF's P/E ratio is 24.54. In terms of profitability, TRUMY's ROE is +0.09%, compared to TCHBF's ROE of +0.05%. Regarding short-term risk, TRUMY is more volatile compared to TCHBF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check TCHBF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, NPRRF has a market cap of 1.6B. Regarding current trading prices, TRUMY is priced at $12.90, while NPRRF trades at $9.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas NPRRF's P/E ratio is 26.92. In terms of profitability, TRUMY's ROE is +0.09%, compared to NPRRF's ROE of N/A. Regarding short-term risk, TRUMY is more volatile compared to NPRRF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check NPRRF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, BOEUF has a market cap of 1.5B. Regarding current trading prices, TRUMY is priced at $12.90, while BOEUF trades at $22.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas BOEUF's P/E ratio is 98.10. In terms of profitability, TRUMY's ROE is +0.09%, compared to BOEUF's ROE of +0.18%. Regarding short-term risk, TRUMY is less volatile compared to BOEUF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check BOEUF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, TGLVY has a market cap of 1.3B. Regarding current trading prices, TRUMY is priced at $12.90, while TGLVY trades at $0.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas TGLVY's P/E ratio is 31.51. In terms of profitability, TRUMY's ROE is +0.09%, compared to TGLVY's ROE of +0.03%. Regarding short-term risk, TRUMY is less volatile compared to TGLVY. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check TGLVY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SAFLY has a market cap of 1.2B. Regarding current trading prices, TRUMY is priced at $12.90, while SAFLY trades at $4.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SAFLY's P/E ratio is 15.38. In terms of profitability, TRUMY's ROE is +0.09%, compared to SAFLY's ROE of +0.11%. Regarding short-term risk, TRUMY is more volatile compared to SAFLY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SAFLY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, BITGF has a market cap of 1.2B. Regarding current trading prices, TRUMY is priced at $12.90, while BITGF trades at $15.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas BITGF's P/E ratio is 45.50. In terms of profitability, TRUMY's ROE is +0.09%, compared to BITGF's ROE of +0.05%. Regarding short-term risk, TRUMY is more volatile compared to BITGF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check BITGF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, PBHDF has a market cap of 1.2B. Regarding current trading prices, TRUMY is priced at $12.90, while PBHDF trades at $19.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas PBHDF's P/E ratio is 12.74. In terms of profitability, TRUMY's ROE is +0.09%, compared to PBHDF's ROE of +0.07%. Regarding short-term risk, TRUMY is more volatile compared to PBHDF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check PBHDF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, TDVXF has a market cap of 912M. Regarding current trading prices, TRUMY is priced at $12.90, while TDVXF trades at $8.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas TDVXF's P/E ratio is 50.82. In terms of profitability, TRUMY's ROE is +0.09%, compared to TDVXF's ROE of +0.32%. Regarding short-term risk, TRUMY is less volatile compared to TDVXF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check TDVXF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SAFLF has a market cap of 906.4M. Regarding current trading prices, TRUMY is priced at $12.90, while SAFLF trades at $2.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SAFLF's P/E ratio is 17.77. In terms of profitability, TRUMY's ROE is +0.09%, compared to SAFLF's ROE of +0.11%. Regarding short-term risk, TRUMY is more volatile compared to SAFLF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SAFLF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, KSRBF has a market cap of 841.7M. Regarding current trading prices, TRUMY is priced at $12.90, while KSRBF trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas KSRBF's P/E ratio is 33.29. In terms of profitability, TRUMY's ROE is +0.09%, compared to KSRBF's ROE of +0.04%. Regarding short-term risk, TRUMY is more volatile compared to KSRBF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check KSRBF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, HGYMF has a market cap of 754.4M. Regarding current trading prices, TRUMY is priced at $12.90, while HGYMF trades at $34.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas HGYMF's P/E ratio is 184.16. In terms of profitability, TRUMY's ROE is +0.09%, compared to HGYMF's ROE of +0.00%. Regarding short-term risk, TRUMY is more volatile compared to HGYMF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check HGYMF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, GRRMF has a market cap of 748.1M. Regarding current trading prices, TRUMY is priced at $12.90, while GRRMF trades at $21.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas GRRMF's P/E ratio is 27.42. In terms of profitability, TRUMY's ROE is +0.09%, compared to GRRMF's ROE of +0.02%. Regarding short-term risk, TRUMY is more volatile compared to GRRMF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check GRRMF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, NNCSF has a market cap of 664.3M. Regarding current trading prices, TRUMY is priced at $12.90, while NNCSF trades at $2.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas NNCSF's P/E ratio is 43.80. In terms of profitability, TRUMY's ROE is +0.09%, compared to NNCSF's ROE of +0.10%. Regarding short-term risk, TRUMY is more volatile compared to NNCSF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check NNCSF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, JNDOF has a market cap of 531M. Regarding current trading prices, TRUMY is priced at $12.90, while JNDOF trades at $22.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas JNDOF's P/E ratio is 47.40. In terms of profitability, TRUMY's ROE is +0.09%, compared to JNDOF's ROE of +0.29%. Regarding short-term risk, TRUMY is more volatile compared to JNDOF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check JNDOF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SPMXF has a market cap of 458.6M. Regarding current trading prices, TRUMY is priced at $12.90, while SPMXF trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SPMXF's P/E ratio is -15.00. In terms of profitability, TRUMY's ROE is +0.09%, compared to SPMXF's ROE of -0.07%. Regarding short-term risk, TRUMY is less volatile compared to SPMXF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check SPMXF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, CLHLF has a market cap of 365.5M. Regarding current trading prices, TRUMY is priced at $12.90, while CLHLF trades at $61.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas CLHLF's P/E ratio is 27.93. In terms of profitability, TRUMY's ROE is +0.09%, compared to CLHLF's ROE of +0.14%. Regarding short-term risk, TRUMY is more volatile compared to CLHLF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check CLHLF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, TSNLF has a market cap of 287.6M. Regarding current trading prices, TRUMY is priced at $12.90, while TSNLF trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas TSNLF's P/E ratio is 27.27. In terms of profitability, TRUMY's ROE is +0.09%, compared to TSNLF's ROE of +0.24%. Regarding short-term risk, TRUMY is less volatile compared to TSNLF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check TSNLF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, GUERF has a market cap of 281M. Regarding current trading prices, TRUMY is priced at $12.90, while GUERF trades at $22.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas GUERF's P/E ratio is 8.19. In terms of profitability, TRUMY's ROE is +0.09%, compared to GUERF's ROE of +0.04%. Regarding short-term risk, TRUMY is more volatile compared to GUERF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check GUERF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, OPSSF has a market cap of 247.4M. Regarding current trading prices, TRUMY is priced at $12.90, while OPSSF trades at $2.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas OPSSF's P/E ratio is -26.74. In terms of profitability, TRUMY's ROE is +0.09%, compared to OPSSF's ROE of -0.36%. Regarding short-term risk, TRUMY is more volatile compared to OPSSF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check OPSSF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, EEOIF has a market cap of 63.4M. Regarding current trading prices, TRUMY is priced at $12.90, while EEOIF trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas EEOIF's P/E ratio is -2.42. In terms of profitability, TRUMY's ROE is +0.09%, compared to EEOIF's ROE of N/A. Regarding short-term risk, TRUMY is more volatile compared to EEOIF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check EEOIF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, OTCFF has a market cap of 16.1M. Regarding current trading prices, TRUMY is priced at $12.90, while OTCFF trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas OTCFF's P/E ratio is -10.14. In terms of profitability, TRUMY's ROE is +0.09%, compared to OTCFF's ROE of +1.24%. Regarding short-term risk, TRUMY is more volatile compared to OTCFF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check OTCFF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, UEEC has a market cap of 15M. Regarding current trading prices, TRUMY is priced at $12.90, while UEEC trades at $0.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas UEEC's P/E ratio is -2.90. In terms of profitability, TRUMY's ROE is +0.09%, compared to UEEC's ROE of +1.00%. Regarding short-term risk, TRUMY is less volatile compared to UEEC. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check UEEC's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, BLMHF has a market cap of 5.2M. Regarding current trading prices, TRUMY is priced at $12.90, while BLMHF trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas BLMHF's P/E ratio is 1.56. In terms of profitability, TRUMY's ROE is +0.09%, compared to BLMHF's ROE of N/A. Regarding short-term risk, TRUMY is more volatile compared to BLMHF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check BLMHF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, PXMVF has a market cap of 4.6M. Regarding current trading prices, TRUMY is priced at $12.90, while PXMVF trades at $1.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas PXMVF's P/E ratio is -0.17. In terms of profitability, TRUMY's ROE is +0.09%, compared to PXMVF's ROE of -6.46%. Regarding short-term risk, TRUMY is less volatile compared to PXMVF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check PXMVF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, CBSC has a market cap of 4.5M. Regarding current trading prices, TRUMY is priced at $12.90, while CBSC trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas CBSC's P/E ratio is -4.00. In terms of profitability, TRUMY's ROE is +0.09%, compared to CBSC's ROE of +0.93%. Regarding short-term risk, TRUMY is more volatile compared to CBSC. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check CBSC's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, MCDA has a market cap of 4.2M. Regarding current trading prices, TRUMY is priced at $12.90, while MCDA trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas MCDA's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to MCDA's ROE of N/A. Regarding short-term risk, TRUMY is more volatile compared to MCDA. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check MCDA's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, GVDI has a market cap of 4.2M. Regarding current trading prices, TRUMY is priced at $12.90, while GVDI trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas GVDI's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to GVDI's ROE of +0.00%. Regarding short-term risk, TRUMY is more volatile compared to GVDI. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check GVDI's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, RSCF has a market cap of 4M. Regarding current trading prices, TRUMY is priced at $12.90, while RSCF trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas RSCF's P/E ratio is -4.66. In terms of profitability, TRUMY's ROE is +0.09%, compared to RSCF's ROE of +0.03%. Regarding short-term risk, TRUMY is more volatile compared to RSCF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check RSCF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, NSTGQ has a market cap of 3.3M. Regarding current trading prices, TRUMY is priced at $12.90, while NSTGQ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas NSTGQ's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to NSTGQ's ROE of N/A. Regarding short-term risk, TRUMY is less volatile compared to NSTGQ. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check NSTGQ's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, TUTH has a market cap of 3M. Regarding current trading prices, TRUMY is priced at $12.90, while TUTH trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas TUTH's P/E ratio is -1.18. In terms of profitability, TRUMY's ROE is +0.09%, compared to TUTH's ROE of +0.27%. Regarding short-term risk, TRUMY is more volatile compared to TUTH. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check TUTH's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, ECIA has a market cap of 1.9M. Regarding current trading prices, TRUMY is priced at $12.90, while ECIA trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas ECIA's P/E ratio is -5.00. In terms of profitability, TRUMY's ROE is +0.09%, compared to ECIA's ROE of -0.22%. Regarding short-term risk, TRUMY is more volatile compared to ECIA. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check ECIA's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, YBGJ has a market cap of 1.8M. Regarding current trading prices, TRUMY is priced at $12.90, while YBGJ trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas YBGJ's P/E ratio is -0.75. In terms of profitability, TRUMY's ROE is +0.09%, compared to YBGJ's ROE of +0.39%. Regarding short-term risk, TRUMY is less volatile compared to YBGJ. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check YBGJ's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, OJSY has a market cap of 454.3K. Regarding current trading prices, TRUMY is priced at $12.90, while OJSY trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas OJSY's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to OJSY's ROE of N/A. Regarding short-term risk, TRUMY is more volatile compared to OJSY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check OJSY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, PDMI has a market cap of 324.9K. Regarding current trading prices, TRUMY is priced at $12.90, while PDMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas PDMI's P/E ratio is -0.01. In terms of profitability, TRUMY's ROE is +0.09%, compared to PDMI's ROE of +0.19%. Regarding short-term risk, TRUMY is more volatile compared to PDMI. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check PDMI's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, WHSI has a market cap of 182.7K. Regarding current trading prices, TRUMY is priced at $12.90, while WHSI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas WHSI's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to WHSI's ROE of +0.84%. Regarding short-term risk, TRUMY is more volatile compared to WHSI. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check WHSI's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, BLFE has a market cap of 156.7K. Regarding current trading prices, TRUMY is priced at $12.90, while BLFE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas BLFE's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to BLFE's ROE of +3.67%. Regarding short-term risk, TRUMY is more volatile compared to BLFE. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check BLFE's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, QTXB has a market cap of 118K. Regarding current trading prices, TRUMY is priced at $12.90, while QTXB trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas QTXB's P/E ratio is -0.05. In terms of profitability, TRUMY's ROE is +0.09%, compared to QTXB's ROE of +0.19%. Regarding short-term risk, TRUMY is less volatile compared to QTXB. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check QTXB's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, IMTH has a market cap of 89.8K. Regarding current trading prices, TRUMY is priced at $12.90, while IMTH trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas IMTH's P/E ratio is -0.03. In terms of profitability, TRUMY's ROE is +0.09%, compared to IMTH's ROE of -0.32%. Regarding short-term risk, TRUMY is less volatile compared to IMTH. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check IMTH's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, LANZ has a market cap of 74.5K. Regarding current trading prices, TRUMY is priced at $12.90, while LANZ trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas LANZ's P/E ratio is 2.70. In terms of profitability, TRUMY's ROE is +0.09%, compared to LANZ's ROE of +0.01%. Regarding short-term risk, TRUMY is less volatile compared to LANZ. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check LANZ's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, CEOS has a market cap of 35.9K. Regarding current trading prices, TRUMY is priced at $12.90, while CEOS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas CEOS's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to CEOS's ROE of +0.40%. Regarding short-term risk, TRUMY is less volatile compared to CEOS. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check CEOS's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, GMVDF has a market cap of 26K. Regarding current trading prices, TRUMY is priced at $12.90, while GMVDF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas GMVDF's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to GMVDF's ROE of +3.68%. Regarding short-term risk, TRUMY is more volatile compared to GMVDF. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check GMVDF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, REMI has a market cap of 14K. Regarding current trading prices, TRUMY is priced at $12.90, while REMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas REMI's P/E ratio is -0.07. In terms of profitability, TRUMY's ROE is +0.09%, compared to REMI's ROE of -0.11%. Regarding short-term risk, TRUMY is less volatile compared to REMI. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check REMI's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SDCCQ has a market cap of 13.4K. Regarding current trading prices, TRUMY is priced at $12.90, while SDCCQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SDCCQ's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to SDCCQ's ROE of -0.61%. Regarding short-term risk, TRUMY is more volatile compared to SDCCQ. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SDCCQ's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, MDIT has a market cap of 8.7K. Regarding current trading prices, TRUMY is priced at $12.90, while MDIT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas MDIT's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to MDIT's ROE of -0.99%. Regarding short-term risk, TRUMY is more volatile compared to MDIT. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check MDIT's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, ASFX has a market cap of 7K. Regarding current trading prices, TRUMY is priced at $12.90, while ASFX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas ASFX's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to ASFX's ROE of +0.00%. Regarding short-term risk, TRUMY is less volatile compared to ASFX. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check ASFX's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, DGEN has a market cap of 3.9K. Regarding current trading prices, TRUMY is priced at $12.90, while DGEN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas DGEN's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to DGEN's ROE of +0.05%. Regarding short-term risk, TRUMY is more volatile compared to DGEN. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check DGEN's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SVSO has a market cap of 2.6K. Regarding current trading prices, TRUMY is priced at $12.90, while SVSO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SVSO's P/E ratio is -0.01. In terms of profitability, TRUMY's ROE is +0.09%, compared to SVSO's ROE of +0.17%. Regarding short-term risk, TRUMY is more volatile compared to SVSO. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SVSO's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, LFPI has a market cap of 2.1K. Regarding current trading prices, TRUMY is priced at $12.90, while LFPI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas LFPI's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to LFPI's ROE of -4.85%. Regarding short-term risk, TRUMY is less volatile compared to LFPI. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check LFPI's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, INND has a market cap of 1.8K. Regarding current trading prices, TRUMY is priced at $12.90, while INND trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas INND's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to INND's ROE of +0.12%. Regarding short-term risk, TRUMY is less volatile compared to INND. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check INND's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SEYE has a market cap of 1.2K. Regarding current trading prices, TRUMY is priced at $12.90, while SEYE trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SEYE's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to SEYE's ROE of N/A. Regarding short-term risk, TRUMY is more volatile compared to SEYE. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SEYE's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, BGMD has a market cap of 1.1K. Regarding current trading prices, TRUMY is priced at $12.90, while BGMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas BGMD's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to BGMD's ROE of +7.47%. Regarding short-term risk, TRUMY is more volatile compared to BGMD. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check BGMD's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, ADLI has a market cap of 1K. Regarding current trading prices, TRUMY is priced at $12.90, while ADLI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas ADLI's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to ADLI's ROE of +1.36%. Regarding short-term risk, TRUMY is less volatile compared to ADLI. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check ADLI's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, VSMD has a market cap of 802. Regarding current trading prices, TRUMY is priced at $12.90, while VSMD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas VSMD's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to VSMD's ROE of +3.15%. Regarding short-term risk, TRUMY is less volatile compared to VSMD. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check VSMD's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, TEVNF has a market cap of 744. Regarding current trading prices, TRUMY is priced at $12.90, while TEVNF trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas TEVNF's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to TEVNF's ROE of +3.22%. Regarding short-term risk, TRUMY is less volatile compared to TEVNF. This indicates potentially lower risk in terms of short-term price fluctuations for TRUMY.Check TEVNF's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, HRAL has a market cap of 396. Regarding current trading prices, TRUMY is priced at $12.90, while HRAL trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas HRAL's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to HRAL's ROE of +0.18%. Regarding short-term risk, TRUMY is more volatile compared to HRAL. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check HRAL's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, MICRD has a market cap of 317. Regarding current trading prices, TRUMY is priced at $12.90, while MICRD trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas MICRD's P/E ratio is -0.00. In terms of profitability, TRUMY's ROE is +0.09%, compared to MICRD's ROE of -0.25%. Regarding short-term risk, TRUMY is more volatile compared to MICRD. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check MICRD's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, RGBOQ has a market cap of 97. Regarding current trading prices, TRUMY is priced at $12.90, while RGBOQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas RGBOQ's P/E ratio is -0.00. In terms of profitability, TRUMY's ROE is +0.09%, compared to RGBOQ's ROE of N/A. Regarding short-term risk, TRUMY is more volatile compared to RGBOQ. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check RGBOQ's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, SECI has a market cap of 31. Regarding current trading prices, TRUMY is priced at $12.90, while SECI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas SECI's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to SECI's ROE of -0.00%. Regarding short-term risk, TRUMY is more volatile compared to SECI. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check SECI's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, VTEQ has a market cap of 1. Regarding current trading prices, TRUMY is priced at $12.90, while VTEQ trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas VTEQ's P/E ratio is -0.00. In terms of profitability, TRUMY's ROE is +0.09%, compared to VTEQ's ROE of N/A. Regarding short-term risk, TRUMY is more volatile compared to VTEQ. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check VTEQ's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, OCPNY has a market cap of 0. Regarding current trading prices, TRUMY is priced at $12.90, while OCPNY trades at $18.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas OCPNY's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to OCPNY's ROE of +0.26%. Regarding short-term risk, TRUMY is more volatile compared to OCPNY. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check OCPNY's competition here

TRUMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, TRUMY stands at 19B. In comparison, MEDVD has a market cap of 0. Regarding current trading prices, TRUMY is priced at $12.90, while MEDVD trades at $0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

TRUMY currently has a P/E ratio of 23.02, whereas MEDVD's P/E ratio is N/A. In terms of profitability, TRUMY's ROE is +0.09%, compared to MEDVD's ROE of N/A. Regarding short-term risk, TRUMY is more volatile compared to MEDVD. This indicates potentially higher risk in terms of short-term price fluctuations for TRUMY.Check MEDVD's competition here